Callan Family Office LLC Decreases Stock Holdings in Haleon PLC Sponsored ADR $HLN

Callan Family Office LLC lessened its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 11.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 670,972 shares of the company’s stock after selling 88,552 shares during the quarter. Callan Family Office LLC’s holdings in Haleon were worth $6,019,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Bank of America Corp DE boosted its position in shares of Haleon by 116.7% during the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after acquiring an additional 6,669,923 shares in the last quarter. Acadian Asset Management LLC lifted its stake in Haleon by 3,031.5% during the second quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock worth $55,813,000 after purchasing an additional 5,212,711 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Haleon by 3,548.4% in the second quarter. BNP Paribas Financial Markets now owns 1,684,968 shares of the company’s stock valued at $17,473,000 after purchasing an additional 1,638,784 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Haleon by 15.5% in the second quarter. JPMorgan Chase & Co. now owns 8,776,686 shares of the company’s stock valued at $91,014,000 after purchasing an additional 1,174,813 shares during the last quarter. Finally, Rockefeller Capital Management L.P. raised its holdings in Haleon by 1,182.6% during the second quarter. Rockefeller Capital Management L.P. now owns 1,197,068 shares of the company’s stock worth $12,414,000 after purchasing an additional 1,103,738 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Price Performance

Shares of HLN opened at $10.50 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. Haleon PLC Sponsored ADR has a fifty-two week low of $8.71 and a fifty-two week high of $11.42. The firm has a 50-day simple moving average of $9.96 and a 200-day simple moving average of $9.64. The company has a market capitalization of $46.74 billion, a price-to-earnings ratio of 26.91 and a beta of 0.19.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research note on Tuesday, January 20th. Hsbc Global Res raised Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Finally, Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.33.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.